Evercon 0.25 Tablets Evercon 0.25 contains Everolimus, a selective mammalian target of rapamycin (mTOR) inhibitor. It binds to the intracellular protein FKBP-12 to form a complex that inhibits the mTOR complex-1 (mTORC1) signaling pathway. This inhibition suppresses T-cell and B-cell proliferation, vascular endothelial growth factor (VEGF) expression, and tumor cell angiogenesis. It is indicated for the prophylaxis of organ rejection in adult patients receiving allogeneic renal or cardiac transplants (in combination with cyclosporine and corticosteroids), as well as for treating certain advanced hormone-receptor positive breast cancers, neuroendocrine tumors, and renal cell carcinoma.